A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing
Cell Reports (2018), 22 (9), 2227-2235
Authors: David V. Morrissey, et al.
Published February 27, 2018
DOI: 10.1016/j.celrep.2018.02.014
LP01 can significantly reduce liver bioaccumulation compared to levels observed with other ionizable lipids such as MC3.